Table 2.
Adverse Events After Initiation of Axitinib
| All patients (n=22) | TKI(−) (n=11) | TKI(+) (n=11) | ||||
|---|---|---|---|---|---|---|
| All grades | ≥Grade 3 | All grades | ≥Grade 3 | All grades | ≥Grade 3 | |
| Hypertension | 18 (81.8) | 8 (36.4) | 9 (81.8) | 4 (36.4) | 9 (81.8) | 4 (36.4) |
| Diarrhea | 17 (77.3) | 4 (18.2) | 10 (90.9) | 3 (27.3) | 7 (63.6) | 1 (9.1) |
| Hypothyroidism | 12 (54.5) | 4 (18.2) | 7 (63.6) | 3 (27.3) | 5 (45.4) | 1 (9.1) |
| Proteinuria | 10 (45.5) | 4 (18.2) | 6 (54.5) | 3 (27.3) | 4 (36.4) | 1 (9.1) |
| Hand–foot syndrome | 8 (36.4) | –A | 5 (45.4) | –A | 3 (27.3) | –A |
| Hoarseness | 6 (27.3) | 0 | 4 (36.4) | 0 | 2 (18.2) | 0 |
| Appetite loss | 6 (27.3) | 0 | 4 (36.4) | 0 | 2 (18.2) | 0 |
| Fatigue | 4 (18.2) | 0 | 2 (18.2) | 0 | 2 (18.2) | 0 |
| Fever | 2 (9.1) | 1 (4.5) | 1 (9.1) | 1 (9.1) | 1 (9.1) | 0 |
| Vomiting | 2 (9.1) | 0 | 1 (9.1) | 0 | 1 (9.1) | 0 |
| Sinusitis | 1 (9.1) | 0 | 0 | 0 | 1 (9.1) | 0 |
| Stomatitis | 1 (9.1) | 0 | 0 | 0 | 1 (9.1) | 0 |
| Otitis externa | 1 (4.5) | 1 (4.5) | 1 (9.1) | 1 (9.1) | 0 | 0 |
| Cerebral infarct | 1 (4.5) | 1 (4.5) | 1 (9.1) | 1 (9.1) | 0 | 0 |
Data are presented as n (%). AThere was no classification of ≥Grade 3 for hand–foot syndrome according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. TKI, tyrosine kinase inhibitor.